| Study | n | SJ* | TJ* | CRP (mg/ml) | HAQ | VAS pain 0–100 | VAS DAS 0–100 |
| Adalimumab + MTX | |||||||
| Weinblatt, 200316 | 67 | 26.2 (5.4) | 41.2 (5.9) | 21 (2.2) | 1.55 (0.07) | 53.0 (2.7) | 56.9 (2.6) |
| Furst, 200318 | 318 | 31.7 (5.7) | 40.1 (5.9) | 15 (1.1) | 1.37 (0.03) | 55.1 (1.3) | 53.9 (1.3) |
| Keystone, 200417 | 207 | 29.2 (5.6) | 40.1 (5.9) | 18 (1.6) | 1.45 (0.04) | 55.9 (1.4) | 52.7 (1.5) |
| DREAM study | 186 | 29.5 (8.6) | 32.3 (8.8) | 21 (2.0) | 1.3 (0.05) | 60.2 (1.8) | 60.6 (1.6) |
| Adalimumab mono | |||||||
| Van de Putte, 200319 | 70 | 28.3 (5.5) | 45.6 (6.0) | 56 (4.7) | 1.74 (0.8) | 73.4 (2.3) | 64.8 (2.2) |
| Van de Putte, 200420 | 113 | 31.1 (5.7) | 50.0 (6.0) | 53 (3.5) | 1.83 (0.06) | 70.1 (1.9) | 72.5 (1.8) |
| DREAM study | 31 | 29.3 (8.6) | 30.6 (8.7) | 26 (4.9) | 1.5 (0.12) | 57.3 (3.9) | 55.2 (3.5) |
| Etanercept + MTX | |||||||
| Weinblatt, 199910 | 59 | 29.4 | 39.4 | 22 | 1.5 | 50.0 | 60.0 |
| Lan, 200411 | 29 | 47.0 (9.4) | 50.0 (9.4) | 17 | 0.99 | 55.2 | 66.2 |
| DREAM study | 171 | 36.1 (9.1) | 32.3 (8.8) | 19 (1.7) | 1.3 (0.06) | 60.3 (1.9) | 59.9 (1.8) |
| Etanercept mono | |||||||
| Moreland, 19974 | 44 | 35.3 (5.8) | 42.3 (5.9) | 36 | 1.35 | 63 | 65 |
| Moreland, 199912 | 78 | 36.8 (5.8) | 46.5 (5.9) | 47 | 1.6 | 67 | 70 |
| Keystone, 200413 | 153 | 28.2 (5.4) | 41.1 (5.6) | 19 (5.0) | 1.4 | 53 | 60 |
| DREAM study | 45 | 36.3 (9.1) | 35.7 (9.1) | 23 (3.3) | 1.5 (0.09) | 67.4 (3.9) | 68.1 (3.7) |
| Infliximab + MTX | |||||||
| Maini, 199814 | 15 | 24.2 | 30.9 | 42 | 2.0 | 60 | 65 |
| ATTRACT, 99-0415† | 86 | 28.8 (20–46) | 47.1 (24–68) | 31 (13–53) | 1.8 (1.4–2.3) | 70 (56–81) | 66 (49–78) |
| DREAM study | 103 | 31.3 (8.8) | 33.9 (8.9) | 27 (4.0) | 1.4 (0.08) | 58.3 (2.6) | 54.7 (2.6) |
CRP, C-reactive protein; DAS, disease activity score; DREAM, Dutch Rheumatoid Arthritis Monitoring; HAQ, Health Assessment Questionnaire; MTX, methotrexate; RCT, randomised controlled trial; VAS, visual analogue scale.
*Mean numbers of swollen and tender joints were converted to percentage of swollen and tender joints of the total number of joints counted.
†Median values and ranges (age and disease duration) or interquartile ranges (SJ, TJ and CRP).
All data are presented as means and SEs.